| Autor: |
Gaca Z; Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland., Pruc M; Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; Department of Public Health, International European University, Kyiv, Ukraine., Swieczkowski D; Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Poland., Kwaśny A; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. Electronic address: akwasny@gumed.edu.pl., Szarpak L; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States; Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland; Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland., Cubała WJ; Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland. |
| Abstrakt: |
Competing Interests: Declaration of competing interest ZG, MP, DŚ, ŁS: none AK: Grants: Beckley Psytech, GH Research, MSD. WJC: Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Novartis, Orion, Otsuka, Sanofi, Servier Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva, Advisory boards: Angelini, Celon (terminated), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Sanofi |
Full Text from ScienceDirect